Results 81 to 90 of about 274,289 (156)
LifeGroup 1 of PAH patients encompasses patients with a diverse underlying etiological condition, having histological modifications that can affect gas exchange across the alveolar-capillary membrane, as reflected by decreased DLCO.
Effrosyni Dima +12 more
doaj +1 more source
Persistent Vascular Collagen Accumulation Alters Hemodynamic Recovery from Chronic Hypoxia [PDF]
, 2012 Pulmonary arterial hypertension (PAH) is caused by narrowing and stiffening of the pulmonary arteries that increase pulmonary vascular impedance (PVZ). In particular, small arteries narrow and large arteries stiffen. Large pulmonary artery (PA) stiffness
Chesler, Naomi C. +5 more
core +2 more sources
Scientific ReportsTargeted vasopeptide therapies have significantly advanced the management of pulmonary arterial hypertension (PAH). However, due to insufficient preclinical evidence regarding the involvement of the endothelin-1 (ET-1) pathway in chronic thromboembolic ...
Benchenouf Feriel +16 more
doaj +1 more source
Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]
, 2014 The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A +9 more
core +1 more source
DDAH1 regulates apoptosis and angiogenesis in human fetal pulmonary microvascular endothelial cells
Physiological Reports, 2019 Nitric Oxide (NO) is an endogenous pulmonary vasodilator produced by endothelial NO synthase (eNOS). Asymmetric dimethyl L‐arginine (ADMA) is an endogenous inhibitor of eNOS activity.
Jennifer K. Trittmann +3 more
doaj +1 more source
Pulmonary Hypertension Caused by Pulmonary Venous Hypertension [PDF]
Pulmonary Circulation, 2014 The effect of pulmonary venous hypertension (PVH) on the pulmonary circulation is extraordinarily variable, ranging from no impact on pulmonary vascular resistance (PVR) to a marked increase. The reasons for this are unknown. Both acutely reversible pulmonary vasoconstriction and pathological remodeling (especially medial hypertrophy and intimal ...
openaire +3 more sources
Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension [PDF]
, 2016 BACKGROUND: Right ventricular (RV) function is a major determinant of exercise intolerance and outcome in idiopathic pulmonary arterial hypertension (IPAH). The aim of the study was to evaluate the incremental prognostic value of echocardiography of the
Badagliacca, Roberto +11 more
core +1 more source
Sarcopenia in Patients with Chronic Thromboembolic Pulmonary Hypertension
Journal of Cardiovascular Development and DiseaseBackground: Sarcopenia, or loss of skeletal muscle mass, has been associated with poor outcomes (e.g., functional decline, increased mortality, and low quality of life), but its role in CTEPH remains unclear.
Steven Hopkins +8 more
doaj +1 more source
Swiss Medical Weekly, 2003 Pulmonary arterial hypertension (PAH) must be classified into primary pulmonary hypertension and PAH related to other diseases such as collagen vascular diseases, HIV infection or portal hypertension. PAH must also be differentiated from other entities, in particular pulmonary hypertension secondary to thromboembolic diseases, requiring specific ...
openaire +3 more sources
MECHANISMS OF DISEASE Acute Oxygen-Sensing Mechanisms [PDF]
, 2005 JOSEPH PRIESTLEY, ONE OF THE THREE SCIENTISTS CREDITED WITH THE discovery of oxygen, described the death of mice that were deprived of oxygen. However, he was also well aware of the toxicity of too much oxygen, stating, “For as a candle burns much faster
Buckler, Keith J. +3 more
core